Biotech | February 25, 2022
Biohaven licenses Taldefgrobep Alfa from Bristol Myers Squibb
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
It is used to control, prevent and normalize the symptoms associated with Alzheimer's disease, attention disorder, bipolar disorder, Parkinson's disease among others
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
Laglo Soft lotion comes with a unique technology that enhances moisturisation and restructures the skin
NDM disorders are a group of rare, inherited neuromuscular disorders which is characterized by the inability to relax muscles following voluntary contraction
Ascent Meditech has set benchmarks in introducing pain management products in India. The company has embarked on a new marketing campaign as it plans to enter new markets. Rajiv Mistry, Founder & Managing Director, Ascent Group shares his perspective with Thomas C Thottathil on the road ahead for the company and industry
It has a total of 50 ANDA approvals from USFDA
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
Subscribe To Our Newsletter & Stay Updated
